---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-167467"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2024-06-25T23:59:59+00:00"
generated_at: "2026-06-01T02:14:49.776969+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics' WTX-330 Phase 1 shows unconfirmed partial response in melanoma; improved tolerability

## Summary
- WTX-330 achieved 23-fold higher systemic IL-12 prodrug concentration vs rhIL-12 at 0.024 mg/kg; free IL-12 <1.6% of prodrug (cutoff June 12, 2024).
- Unconfirmed partial response in metastatic melanoma patient who had progressed on adjuvant pembrolizumab; confirmatory scan pending.
- Two MSS CRC patients achieved stable disease (one for 24 weeks); evidence of CD8+ T and NK cell activation in tumor biopsies.
- No Grade 4/5 treatment-related AEs; mild-moderate toxicities (fever, chills, cytopenias) primarily first dose; MTD not established.
- Expansion arms open at 0.024 mg/kg for ICI-resistant or ICI-naive patients; additional data expected Q4 2024.

## SEC filing metadata
- accession: 0001193125-24-167467
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2024-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312524167467/0001193125-24-167467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312524167467/d857404d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-167467
- JSON: https://secwatch.observer/filing/0001193125-24-167467.json
- Plain text: https://secwatch.observer/filing/0001193125-24-167467.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.